Regeneron — Deal History & Benchmarks
Market Analysis
Regeneron has been involved in 4 transactions totaling $16.5B across Rare Disease, Cardiovascular, Immunology & Autoimmune. As both a licensor and licensee, they have demonstrated a collaborative partnership model.
Key transactions include Sanofi ($13B, 2024), Alnylam ($1.4B, 2024), Alnylam Pharmaceuticals ($1.4B, 2024).
Their deal activity is concentrated in Cardiovascular (50%) with RNAi and PCSK9 Targeting assets representing their most common deal types.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How many deals has Regeneron done?
What is Regeneron's typical deal structure?
What therapeutic areas does Regeneron focus on?
How has Regeneron's deal activity trended over time?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.